Identification of clinical strategies that limit early islet loss and enhance long-term islet survival and function continue to be critical to the field of islet transplantation. The Clinical Component of this proposal will focus on treating islets pre-transplant, and recipients (during and post-transplant), with selected agents with a unique spectrum of anti-inflammatory, anti-apoptotic and beta cell enhancing properties (Lisofylline and Exenatide), to improve beta cell function and viability, maximizing pre-transplant functional islet mass, islet engraftment and long-term function, in patients with Type 1 diabetes. In order to clearly ascertain the effect of newly introduced agents, such as lisofylline (LSF) and Exenatide (EXN), on transplant outcome (CIT-02), it is essential to address issues related to immunological alterations (auto/allo reactivity) and metabolic function in order to compare the results to those of control subjects in CIT07. The central hypothesis of this application is that identification of reliable indicators of post-transplant metabolic function, as well as immune status, will enhance our ability to predict islet allograft dysfunction in patients with type 1 diabetes mellitus, thereby allowing for alteration of therapy to enhance islet engraftment, function and long-term survival.
Aim 1 : To assess islet engraftment, metabolic function and long-term survival in CIT07 control subjects by undertaking additional metabolic tests that we have previously observed to be early indicators of graft dysfunction and comparing the results obtained to data from CIT02 subjects.
Aim 2 : To undertake additional immune monitoring strategies in CIT07 patients that allow us to verify the efficacy of immune-suppression and/or identify perturbations of the immune system which precede early loss of function, rejection, or recurrent autoimmunity and comparing the results obtained to data from CIT02 subjects.
Aim 3 : To utilize the information obtained from these studies to clearly identify new metabolic and immunologic testing strategies that provide information that is superior to that attainable with more established assays;i.e., the data enables alteration of therapies to achieve enhanced graft survival
(provided by the applicant): The identification of clinical interventions that will allow the survival of transplanted Islets is crucial to allow for better outcomes of Islet Transplantations. In addition to improving Islet survival at the time of transplantation there's a need for new immunosuppressive modalities that will protect Islets from being destroyed by the immune system and therefore leading to long term Islet function.
| Foster, Eric D; Bridges, Nancy D; Feurer, Irene D et al. (2018) Improved Health-Related Quality of Life in a Phase 3 Islet Transplantation Trial in Type 1 Diabetes Complicated by Severe Hypoglycemia. Diabetes Care 41:1001-1008 |
| NIH CIT Consortium Chemistry Manufacturing Controls Monitoring Committee ; NIH CIT Consortium (2017) Purified Human Pancreatic Islets, CIT Transplant Media with Lisofylline or Exenatide. CellR4 Repair Replace Regen Reprogram 5: |
| NIH CIT Consortium Chemistry Manufacturing Controls Monitoring Committee ; NIH CIT Consortium (2017) Purified Human Pancreatic Islets Master Production Batch Record, Part 1 University of Illinois, Chicago & University of Miami (Product Codes PHPI-A-01 & PHPI-L-01). CellR4 Repair Replace Regen Reprogram 5: |
| NIH CIT Consortium Chemistry Manufacturing Controls Monitoring Committee ; NIH CIT Consortium (2017) PHPI, MPBR, Part 2B (Product Code PHPI-L-01 or PHPI-E-01, Islets with Lisofylline or Exenatide). CellR4 Repair Replace Regen Reprogram 5: |
| NIH CIT Consortium Chemistry Manufacturing Controls Monitoring Committee ; NIH CIT Consortium (2017) PHPI, MPBR, Part 2A (Product Code PHPI-A-01, Islets Alone). CellR4 Repair Replace Regen Reprogram 5: |
| NIH CIT Consortium Chemistry Manufacturing Controls Monitoring Committee ; NIH CIT Consortium (2017) PHPI, MPBR, Part 2B (Product Code PHPI-L-01, Islets with Lisofylline). CellR4 Repair Replace Regen Reprogram 5: |
| NIH CIT Consortium Chemistry Manufacturing Controls Monitoring Committee ; NIH CIT Consortium (2017) Purified Human Pancreatic Islets with Lisofylline, Interim Certificate of Analysis (Product Code PHPI-L-01). CellR4 Repair Replace Regen Reprogram 5: |
| NIH CIT Consortium Chemistry Manufacturing Controls Monitoring Committee ; NIH CIT Consortium (2017) Purified Human Pancreatic Islets, CIT Transplant Wash Media with Lisofylline. CellR4 Repair Replace Regen Reprogram 5: |
| NIH CIT Consortium Chemistry Manufacturing Controls Monitoring Committee ; NIH CIT Consortium (2017) Raw Material Specification, Exenatide, 250 ?g/mL. CellR4 Repair Replace Regen Reprogram 5: |
| NIH CIT Consortium Chemistry Manufacturing Controls Monitoring Committee ; NIH CIT Consortium (2017) Purified Human Pancreatic Islets with Exenatide, Certificate of Analysis (Product code PHPI-E-01). CellR4 Repair Replace Regen Reprogram 5: |
Showing the most recent 10 out of 120 publications
